Efficacy of Abbott ID NOW COVID-19 Using Fresh Nasopharyngeal Specimens Acquired with a Fine Swab

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Backgrounds: Many reported rates of positive results by nicking enzyme amplification reaction (NEAR) applied together with the Abbott ID NOW™ COVID-19 (AIN) test and dry patient samples is lower than rates provided by other nucleic acid amplification tests. Few studies have used fresh samples, however. Methods: We conducted this retrospective study using fresh samples to determine the correlations among fever, associated symptoms, and the NEAR detection rate. Quarantined cases of suspected SARS-CoV-2 infection at Kunimoto ENT clinic (Jan 14, 2022–May 7, 2023) who had been in close contact with SARS-CoV-2-infected individuals were enrolled. Specimens were collected by the thin-diameter nasal sterile swab from the nasopharynx and examined immediately. We evaluated the positive-result rates, fever, and symptoms. Results: The total number of close-contact patients evaluated was 661 and AIN-positive cases was 427. The detection rate in the fever ≥37.4°C patients was 97% (257/266), significantly higher than the corresponding rate in the <37.4°C patients (170/395) (p<0.00001). The detection rate in the patients with ≤1 symptoms other than fever was 98% (394/402). Conclusions: These results suggest that the AIN results are sufficiently dependable when fresh samples are obtained from patients with a fever ≥37.4°C, and with more than one symptom.

Article activity feed